Dr. Peter G. Czarnecki, M.D., Beth Israel Deaconess Medical Center

“Ciliary Targeting of Polycystins in the Context of IFT-A Complex Mutations”

Dr. Kai He, Ph.D., Mayo Clinic, Rochester

“Defining Axoneme Polyglutamylation as a Novel Therapeutic Target for ADPKD”

Dr. Katharina Hopp, Ph.D., University of Colorado, Denver Anschutz Medical Campus

“Defining MCJ as a Novel Therapeutic Target for ADPKD”

Dr. Muthusamy Thangaraju, Ph.D., Augusta University

“Netrin-1 is a New and Novel Biomarker and a Potential Therapeutic Target for the ADPKD Cystogenesis”